S1435-119

Introduced

To prohibit the use of taxpayer dollars to support animal experimentation in the laboratories of adversarial nations.

119th Congress Introduced Apr 10, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill prohibits the Department of Health and Human Services (HHS) from using taxpayer money to conduct or fund biomedical research involving animal testing in adversarial nations. The prohibition covers both direct government research and grants/contracts to entities in those countries. Named countries include China (including Hong Kong), Iran, North Korea, and Russia, with authority for HHS to add more.

Who Benefits and How

Domestic research institutions and laboratories benefit as federal research funding that might otherwise flow to foreign competitors will instead stay within the United States. National security interests are served by preventing potential dual-use research from being conducted in adversarial nations. Animal welfare advocates concerned about overseas research standards may view this as a positive restriction.

Who Bears the Burden and How

HHS and NIH face new compliance requirements to ensure no funds flow to prohibited countries. U.S. research institutions with international collaborations involving animal research in named countries must restructure or terminate those partnerships. Pharmaceutical and biotech companies relying on cost-effective overseas animal testing must find alternative arrangements.

Key Provisions

  • Prohibits HHS from directly or indirectly conducting animal research in China, Iran, North Korea, or Russia
  • Bans federal grants, contracts, and cooperative agreements funding animal research by entities in those countries
  • Authorizes HHS Secretary to designate additional foreign countries of concern
  • Requires Congressional reporting within 60 days when new countries are designated

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.

At a Glance

What This Bill Does

Prohibits the use of federal taxpayer dollars to fund or conduct biomedical animal research in adversarial foreign nations including China, Iran, North Korea, and Russia

Key Policy Areas

Health, National Security, Foreign Policy, Research & Development

Primary Purpose

Prohibits the use of federal taxpayer dollars to fund or conduct biomedical animal research in adversarial foreign nations including China, Iran, North Korea, and Russia

Policy Domains

Health National Security Foreign Policy Research & Development

Section 2 - Prohibition on funding research on animals in certain foreign countries

Identified Gains
Contextual inference, no direct clause citation
  • Domestic biomedical research institutions
  • U.S. pharmaceutical companies
  • National security interests
Model: N/A | Version: bill_summary_v2 | Source: is

Contextual inference, no direct clause citation

Identified Costs
Contextual inference, no direct clause citation
  • HHS and NIH
  • U.S. research institutions with foreign collaborations
  • Foreign research facilities in named countries
Model: N/A | Version: bill_summary_v2 | Source: is

Contextual inference, no direct clause citation

Legislative Progress

Introduced
Introduced Committee Passed
Apr 10, 2025

Ms. Ernst (for herself and Mr. Schmitt) introduced the following …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Research & Science
3 mentions across 1 clause
+1 positive -2 negative

Contract research organizations (CROs) in adversarial nations, Domestic biomedical research laboratories, U.S. research institutions with foreign animal research collaborations

Positive-direction: Domestic biomedical research laboratories

Negative-direction: Contract research organizations (CROs) in adversarial nations, U.S. research institutions with foreign animal research collaborations

Government
1 mention across 1 clause
-1 negative

HHS and NIH research programs

Manufacturing
1 mention across 1 clause
-1 negative

U.S. pharmaceutical and biotech companies

1/2
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Health National Security Research & Development
Actor Mappings
"the_secretary"
→ Secretary of Health and Human Services

Key Definitions

Terms defined in this bill

1 term
"appropriate committees of Congress" §2(d)

The Committee on Appropriations of the Senate; the Committee on Health, Education, Labor, and Pensions of the Senate; the Committee on Homeland Security and Governmental Affairs of the Senate; the Committee on Appropriations of the House of Representatives; the Committee on Energy and Commerce of the House of Representatives

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology